Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $97.00 | Outperform | Oppenheimer |
| 5/7/2025 | $80.00 | Buy | Chardan Capital Markets |
| 3/3/2025 | $120.00 → $105.00 | Buy | H.C. Wainwright |
| 2/11/2025 | $111.00 | Buy | Deutsche Bank |
| 8/5/2024 | $134.00 | Outperform | Oppenheimer |
| 6/24/2024 | $145.00 | Buy | Needham |
| 6/18/2024 | $155.00 | Buy | Guggenheim |
| 5/1/2024 | $117.00 | Outperform | Robert W. Baird |
Oppenheimer resumed coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $97.00
Chardan Capital Markets initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $80.00
H.C. Wainwright reiterated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $105.00 from $120.00 previously
4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)